Anzeige
Erschienen in:
02.01.2023 | Original Paper
Patients undergoing multiple 18F-FDG PET/CT scans: frequency, clinical indications, and cumulative dose
Erschienen in: Health and Technology | Ausgabe 1/2023
EinloggenAktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.
Wählen Sie Textabschnitte aus um mit Künstlicher Intelligenz passenden Patente zu finden. powered by
Markieren Sie Textabschnitte, um KI-gestützt weitere passende Inhalte zu finden. powered by
Abstract
Objective
To assess frequency, clinical indications, and cumulative effective dose (CED) of patients undergoing multiple 18F-FDG PET/CT imaging.
Methods
Retrospective analysis of 18F-FDG PET/CT scans performed at a university hospital for 11 years was done. The effective dose was estimated from activity administered and dose-length-product.
Results
A total of 55,424 18F-FDG PET/CT scans were performed in 32,658 patients. The average injected activity was 421 MBq and median 417 MBq. 24.2% of the patients were scanned 2–5 times in a year, 16.7% of them being unique patients (not counted as a separate patient in different years). The maximum PET/CT scans in a year for any patient was five. 23,571 (72.2%) patients underwent a single 18 F-FDG PET/CT scan, while 9087 (27.8%) unique patients underwent 2–23 scans during 11 years. 82% of the scanned patients had a malignant disease, and 2.4% of patients with ≥ 2 18 scans in a year had non-malignant indications. 1.4% of patients received CED ≥ 100 mSv in one year from multiple 18 F-FDG PET/CT scans and 0.8% of them received ≥ 100 mSv in a year more than one time, the CED of 27.8% (9087 patients) who underwent 2 to 23 18F-FDG PET/CT scans over 11-years ranged from 38 to 575 mSv (median: 271 mSv).
Conclusion
This largest ever study covering analysis of 11-years’ data of 18F-FDG PET/CT patients showed that a sizeable number of patients, largely with malignant disease (82%) undergo recurrent imaging during one year and non-ignorable fraction exceed 100 mSv in one year.